Vita Therapeutics and I Peace Join Forces to Deliver Gene-Edited Stem Cells for Muscular Dystrophy

The companies will collaborate to leverage gene editing and GMP iPSC manufacturing to hopefully deliver new therapies.

I Peace, Inc. has announced an agreement with Vita Therapeutics to jointly develop universal induced pluripotent stem (iPS) cells for use in new therapies.

The companies plan to generate GMP-grade iPS cells modified using proprietary, licensed gene editing technology from Vita. The approach is to create a base hypoimmune cell line by depleting Class I and II HLA (human leukocyte antigen) genes, which are key markers involved in immune rejection. The companies say they’re going to create these universal cells for patients with facioscapulohumeral muscular dystrophy (FSHD).

  • I Peace will provide its GMP iPS cell-related technology to generate master cell banks (MCBs) for both the parent line and the gene-edited subclones.
  • Vita Therapeutics will supply the gene editing technology and expertise for developing iPSC-derived universal cells.

The resulting MCBs will be registered in the FDA Drug Master File (DMF), a regulatory filing that streamlines the review process for clinical-grade iPSC lines. 

Want to keep up on regenerative medicine? Get the weekly newsletter here.

If you found this post helpful, would you mind sharing it? ⬇️ 

The Latest

FDA’s New Regulatory Pathway May Forego RCTs for Ultra-Rare Conditions

Dr. Marty Makary and Dr. Vinay Prasad publish new article in New England Journal of Medicine, proposing a new pathway. Here are the details.

New Korean Stem Cell Hub Coming to Baltimore, Focused on OA and Alzheimer’s Research

Nature Cell’s new facility will focus on stem cell therapeutics, research, and manufacturing, supported by the Maryland Stem Cell Research Fund.

UK Follows USA’s Bid to End Animal Testing, £75 Million Plan for Alternative Research Methods

Both countries have made similar announcements this year to favor more humane, and human-relevant methods for testing therapies, but the UK seems to lay out more specific plans and timelines.

Aspen Neuroscience Secures $115 Million Funding for Parkinson’s Stem Cell Therapy

The new funding round will help advance their iPSC-derived dopaminergic neuronal precursor cell trials, manufacturing, and continued development of other iPSC therapies.

Related Content:

New Korean Stem Cell Hub Coming to Baltimore, Focused on OA and Alzheimer’s Research

Nature Cell’s new facility will focus on stem cell therapeutics, research, and manufacturing, supported by the Maryland Stem Cell Research Fund.

UK Follows USA’s Bid to End Animal Testing, £75 Million Plan for Alternative Research Methods

Both countries have made similar announcements this year to favor more humane, and human-relevant methods for testing therapies, but the UK seems to lay out more specific plans and timelines.

Aspen Neuroscience Secures $115 Million Funding for Parkinson’s Stem Cell Therapy

The new funding round will help advance their iPSC-derived dopaminergic neuronal precursor cell trials, manufacturing, and continued development of other iPSC therapies.

Interview: siRNA-Loaded Stem Cell Exosomes, Inside NurExone Biologic’s Spinal Cord Injury Candidate

NurExone's SCI candidate showed 100% gait recovery in rat models, and they're gearing up for human trials hopefully in 2026. Enjoy the interview!

TheWell Bioscience Introduces VitroGel® NEURON, a Synthetic Hydrogel Enhancing Neuronal Cell Culture

Designed for 2D and 3D cultures, this platform aims to offer greater consistency and scalability in neuronal research.

Mytos Nabs Cell Manufacturing Deals with StemSight, Rinri Therapeutics, and Novadip

Mytos has developed an automated cell manufacturing platform to serve the cell therapy industry as it matures

Tel Aviv University to Implant Lab-Grown Spinal Cord in Human Trial, Derived from Stem Cells

Researchers have seen good success in animal studies, and are advancing to the first clinical trials in humans. What a time to be alive.

Indiana University Opens New Stem Cell Research Center for Alzheimer’s and Dementias

Indiana University’s new MAP-AD center will use stem-cell-derived brain models and AI to advance Alzheimer’s research and drug development.

Klotho Neurosciences to Acquire Turn Biotechnologies Assets, Secures $300 Million Deal

Klotho Neurosciences expands into cellular reprogramming with a planned Turn Biotechnologies acquisition and significant pharma partnership.

Cell X Technologies and BioLamina Partner on induced pluripotent stem cell (iPSC) Standardization

The collaboration aims to streamline iPSC manufacturing by combining automation with standardized reagents for reproducible, scalable cell therapy processes.

DarwinCell Presents Mesenchymal Stem Cell ALS Therapy at American Neurological Association Meeting

The Chinese biotech company shared promising preclinical and early clinical results for its novel ALS therapy

Aspen Neuroscience Begins Third Cohort in Parkinson’s Disease Stem Cell Therapy Trial with Commercial Formulation

Aspen’s trial advances with a commercial-ready, patient-derived cell therapy aiming to improve Parkinson’s outcomes and streamline clinical delivery.
x
Subscribe
Subscribe

Discover more from Regen Report

Subscribe now to keep reading and get access to the full archive.

Continue reading

Stay updated on Regenerative Medicine

Subscribe